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Abstract
Background: Pin1 has previously been described to regulate cells that participate in both innate and adaptive immunity.
Thus far, however, no role for Pin1 has been described in modulating conventional dendritic cells, innate antigen presenting
cells that potently activate naı ¨ve T cells, thereby bridging innate and adaptive immune responses.
Methodology/Principal Findings: When challenged with LPS, Pin1-null mice failed to accumulate spleen conventional
dendritic cells (cDC). Analysis of steady-state spleen DC populations revealed that Pin1-null mice had fewer CD8+ cDC. This
defect was recapitulated by culturing Pin1-null bone marrow with the DC-instructive cytokine Flt3 Ligand. Additionally,
injection of Flt3 Ligand for 9 days failed to induce robust expansion of CD8+ cDC in Pin1-null mice. Upon infection with
Listeria monocytogenes, Pin1-null mice were defective in stimulating proliferation of adoptively transferred WT CD8+ T cells,
suggesting that decreases in Pin1 null CD8+ cDC may affect T cell responses to infection in vivo. Finally, upon analyzing
expression of proteins involved in DC development, elevated expression of PU.1 was detected in Pin1-null cells, which
resulted from an increase in PU.1 protein half-life.
Conclusions/Significance: We have identified a novel role for Pin1 as a modulator of CD8+ cDC development. Consistent
with reduced numbers of CD8+ cDC in Pin1-null mice, we find that the absence of Pin1 impairs CD8+ T cell proliferation in
response to infection with Listeria monocytogenes. These data suggest that, via regulation of CD8+ cDC production, Pin1
may serve as an important modulator of adaptive immunity.
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Introduction
Pin1is a ubiquitouslyexpressed phosphorylation-specificpeptidyl
prolyl isomerase (PPIase) that regulates substrate function by
catalyzing the cis-trans isomerization of prolyl bonds. The ability of
Pin1 to accelerate this intrinsically slow conformational switch
enables it to function as a molecular timer whose activity appears to
be crucial during events that require rapid or precisely timed
responses [1,2]. Consistent with such a role, Pin1 has been
demonstrated to modulate the timing of primordial germ cell
(PGC) proliferation in mice. In the absence of Pin1, PGC exhibit a
prolonged cell cycle and undergo fewer cell divisions during their 5
day transit towardthe fetal gonad. As a result, bothmaleand female
Pin1-null mice are born with fewer germ cells and display severe
infertility [3]. Additional studies carried out in mouse embryo
fibroblasts (MEF)indicate that thelossof Pin1 both delaysentry into
the cell cycle from quiescence and causes asynchronously growing
cells to stall in the G1/S phase of the cell cycle [4,5,6].
Although multiple mammalian PPIases exist, Pin1 is unique in its
ability to regulate substrates that are phosphorylated. By binding to
phospho-Ser/Thr-Pro motifs, Pin1 has been shown to influence the
dephosphorylation, stability, dimerization, localization, and/or
activity of a diverse set of proteins [1,7]. In addition to regulating
both proliferation and survival in non-hematopoietic cells, Pin1 also
possessesroles in modulating immune cell function. In collaboration
with the Dalla-Favera laboratory, we previously showed that Pin1
regulates Bcl6 expression in germinal center B cells in response to
genotoxic stress [8]. Pin1 also participates in the activation of T cells
by modulating the activity of the transcription factor NFAT and
regulating activation-induced cytokine production [9,10]. Within
the innate immune system, Pin1 has been shown to modulate
allergen-induced cytokine production and survival in lung eosino-
phils [11,12,13]. Pin1 also modulates the turnover of the
transcription factor IRF3 downstream of toll-like receptor (TLR)
3, and Pin1-null mice were defective in producing IFNb when
challenged with poly (I:C) to mimic viral infection [14]. A role for
Pin1 has also been described in regulating endotoxemia and IL-6
mRNA production by activated macrophages [15]. Most recently,
Pin1 was demonstrated to facilitate the production of IFNa in
plasmacytoiddendritic cellsviaregulationofIRAK1activity [16].It
is clear from these reports that Pin1 possesses the ability to regulate
multiple arms of the immune response. Thus far, however, no role
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immunity, conventional dendritic cells.
Dendritic cells (DC) are innate antigen presenting cells that
are particularly adept at activating naı ¨ve T cells and inducing
immunologic memory [17]. Multiple DC subsets have been
identified and differ in tissue distribution, receptor expression, and
function. Conventional DC (cDC) and plasmacytoid DC (pDC)
are two subsets that reside in lymphoid organs in close proximity
to T cells [18]. cDC express multiple TLRs, which enable them to
sense and respond to a variety of pathogens, including bacteria
and virus. These cells are further divided into functional subsets
based on expression of CD8. Those that lack CD8 expression are
most abundant, and thought to primarily activate CD4+ T helper
cell responses. CD8+ cDC are less abundant than CD82 cDC,
and possess the ability to cross-present exogenous antigens to
activate CD8+ T cells [17,19,20]. pDC express TLR7 and TLR9,
which endow them with the ability to respond to viral nucleic
acids. During viral infection, activated pDC support cDC and T
cell function by secreting IFNa/b and T cell chemokines [21].
Dendritic cells develop from both common myeloid and lymphoid
progenitors in the bone marrow, both of which can give rise to the
common DC progenitor (CDP) [22]. This developmental program
is dependent on the cytokine Flt3 Ligand (FL), which binds and
activates the Flt3 receptor on hematopoietic progenitors. The
requirement for this cytokine in DC development has been
demonstrated in mice that lack either FL or Flt3 receptor, both of
which exhibit profound defects in the production of cDC and pDC
[23,24]. Furthermore, administration of FL in vivo has been shown to
induce massive expansion of DC in mice [25]. Efforts aimed at
identifying molecular determinants of DC development and subset
specification are ongoing. Many transcription factors have been
identified that broadly regulate the development of multiple DC
subsets, such as Stat3, which lies downstream of the Flt3 receptor
[26]. Other transcriptional regulators appear to be more specific,
such as Id2, which is reported to facilitate CD8+ cDC development
and inhibit pDC development [27]. More recently, both NFIL3 and
Batf3 have been shown to modulate the development of the CD8+
subset of cDC [19,28]. Because the distinct functions of each DC
subset shape and fine-tune the immune response [29], it is of great
interest to identify specific modulators of subset development and
function.
In this report, we describe a novel role for Pin1 in modulating the
development of the CD8+ subset of cDC. Pin1-null mice have fewer
steady-state CD8+ cDC in their spleens and are impaired in their
ability to expand this subset in vivo in response to FL injection. These
defects are not the result of decreased DC progenitors in the bone
marrow, as Pin1-null bone marrow is comparable to that of WT
mice. However, when Pin1-null bone marrowis cultured ex vivo with
FL, it is defective in generating the CD8+ cDC equivalent subset.
Furthermore, when infected with Listeria monocytogenes (L.m.), Pin1-
null mice exhibit a reduced ability to induce expansion of adoptively
transferred CD8+ T cells. Upon measuring the expression of
transcription factors that regulate DC development, Pin1-null cells
exhibited an increase in PU.1 protein expression, which results, in
part, from decreased protein turnover. Thus, we propose Pin1 to be
an important regulator of CD8+ cDC-dependent immune respons-
es through its preferential modulation of CD8+ cDC development.
Results
Pin1-null mice fail to accumulate spleen cDC in response
to LPS
Pin1 has previously been described to modulate activation and
cytokine production in both eosinophils and T cells [9,11]. Based
on these reports, we initially hypothesized that Pin1-null mice
would exhibit an impaired response to systemic inflammation,
which is characterized by activation of both innate antigen
presenting cells and lymphocytes [30,31]. Systemic inflammation
was induced in mice by injecting the bacterial cell wall component
lipopolysaccharide (LPS), as this is a well-established method to
induce a sterile inflammatory response [32]. Three hours after
LPS injection, blood was collected for measurement of two classic
pro-inflammatory cytokines, IL-6 and TNFa. Pin1-null mice
produced the same amounts of circulating IL-6 and TNFa as WT
mice (Figure 1A).
Next, the presence of B cells, T cells and DC was determined by
staining splenocytes with markers that identified these cell types.
Eighteen hours after LPS injection, total B cells and T cells were
comparable between WT and Pin1-null mice, as well as the LPS-
stimulated expression of the activation marker CD69 (Figure S1).
In contrast, Pin1-null mice that received LPS exhibited a
significant defect in the accumulation of spleen cDC, which are
identified by high expression of both CD11c and MHC class II
(Figure 1B, S1C). Additionally, it appeared that vehicle-injected
Pin1-null mice also had fewer cDC than WT mice, although this is
only a slight trend. As Pin1 has not yet been ascribed any roles in
cDC biology, the possibility that Pin1 could modulate steady-state
cDC production and/or LPS-induced cDC accumulation was
further investigated.
Impaired production of steady-state spleen DC in
Pin1-null mice
To determine whether Pin1-null mice possess fewer steady-state
spleen cDC, spleens were harvested from healthy WT and Pin1-
null mice and stained for multiple DC populations. Pin1-null mice
harbored a significant decrease in the number of both the CD8+
and CD82 subsets of spleen cDC, with the greatest defect in the
CD8+ subset, which is decreased 50% compared to WT cells
(Figure 2A). Upon examining the frequency of these populations,
however, we encountered a slightly different result. While the
frequency of Pin1-null CD8+ cDC remained significantly
decreased compared to WT cells, there was not a significant
decrease in the frequency of Pin1-null CD82 cDC (Figure S2A,
S2B). The discrepancy between total number and frequency of
CD82 cDC may be explained by the observation that Pin1-null
mice tend to have fewer splenocytes than WT mice (Figure S2C).
Although this trend does not reach statistical significance, when
coupled to a trend for decreased frequency, it produces a
significantly different total number. Pin1-null mice also exhibited
a decrease in both the number and frequency pDC but neither of
these differences was statistically significant (Figure 2A, S2A, S2B).
Despite our uncertainty regarding the existence of a defect in Pin1-
null CD82 cDC, the data clearly indicated that the absence of
Pin1 disrupts the ability of CD8+ cDC to populate the spleen
under steady-state conditions.
We next examined a potential role for Pin1 in cDC
development by injecting mice with FL and measuring the
resulting expansion of DC subsets. Mice were injected with 1 mgo f
FL for 9 consecutive days, as has previously been described [33].
On day 10, splenocytes were stained and DC populations were
quantified. Pin1-null mice were unable to expand the CD8+ subset
of cDC to the same extent as WT mice. The FL-induced
accumulation of CD82 cDC, however, was comparable between
WT and Pin1-null mice. This result is consistent with the absence
of a decrease in the frequency of steady-state CD82 cDC in Pin1-
null mice (Figure S2A). Similar to what was observed in the steady-
state, FL-treated Pin1-null mice accumulated fewer pDC, but
again this difference does not reach statistical significance
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are particularly sensitive to the loss of Pin1, as they exhibit the
greatest defect in its absence during both steady-state conditions
and FL-induced expansion in vivo.
Bone marrow progenitors are unaltered in the absence of
Pin1
DC develop from hematopoietic progenitors in the bone
marrow that transition through several stages of development,
becoming increasingly committed to one particular fate with each
subsequent step. To address whether defects existed in bone
marrow progenitors of Pin1-null mice that could account for the
changes observed in the spleen DC populations, bone marrow cells
from WT and Pin1-null mice were stained and analyzed for the
presence of multiple progenitors (schematic of DC development
available in Figure S3). As noted with the number of splenocytes,
Pin1-null mice exhibited a trend for reduced numbers of bone
marrow cells. When corrected for differences in total body weight,
however, these differences no longer existed (Figure 3A). Upon
normalizing by body weight, no defects in the number of Pin1-null
bone marrow progenitors were detected (Figure 3B). These results
are consistent with the frequencies of bone marrow progenitors,
which are also unaltered in Pin1-null mice (Figure S4A).
pDC fully develop within the bone marrow, while pre-cDC
leave the bone marrow and circulate to peripheral tissues where
they undergo the final steps of development to give rise to CD82
or CD8+ cDC (Figure S3). To determine whether defects existed
in these two populations, bone marrow cells were also stained with
markers of pre-cDC and pDC. Consistent with an absence of
defects in bone marrow progenitors, neither of these populations
was perturbed in Pin1-null mice, either in number (Figure 3C) or
frequency (Figure S4B). The absence of a defect in Pin1-null bone
marrow pDC is interesting in light of the trend to have fewer
spleen pDC, and suggests that changes in spleen pDC number are
not the result of impaired development, but may instead arise from
a separate defect. Collectively, our data indicate that the loss of
Pin1 is inconsequential to stages of cDC and pDC development
that take place in the bone marrow, and point to a role for Pin1 in
processes that occur in the periphery.
Loss of Pin1 impairs the ability of cultured bone marrow
to generate cDC
To determine if Pin1 regulates final stages of CD8+ cDC
development that occur outside the bone marrow, and to eliminate
the potential contribution of altered migration to the spleen, an ex
vivo bone marrow culture system was utilized to induce DC
development. WT and Pin1-null bone marrow cells were cultured
in the presence of FL for 9 days, an established regimen that
generates fully developed pDC and cDC subsets that are
functionally equivalent to steady-state populations in vivo. Although
bone marrow-derived cDC do not express CD8, the two subsets
have previously been distinguished from each other by the
presence or absence of the myeloid marker Mac1 [34,35]. When
cultured with FL, Pin1-null bone marrow exhibited a 50%
reduction in the generation of Mac1- (CD8+ equivalent) cDC,
which mirrored what had been observed in vivo (Figure 4A). The
Mac1+ (CD82 equivalent) subset, however, exhibited a more
complex phenotype in the absence of Pin1. Rather than being
Figure 1. Pin1-null mice fail to accumulate spleen cDC after LPS challenge. (A) Circulating IL-6 and TNFa concentrations in WT and Pin1-null
mice 3 hours after administration of 15 mg/kg LPS. Blood was collected either by tail vein bleed, or by cardiac puncture following euthanization.
Samples were analyzed by ELISA (n=6). (B) Representative FACS plots and graph of spleen cDC from WT and Pin1-null mice 18 hours after
administration of either 15 mg/kg LPS or vehicle (HBSS). Graph shows the frequency of spleen cDC from WT and Pin1-null mice as percentage of total
splenocytes (n=6).
doi:10.1371/journal.pone.0029808.g001
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express less CD11c than WT Mac1+ cDC. Indeed, when gated on
the brightest CD11c+ cells, a significant decrease in bone marrow-
derived Mac1+ cDC can be quantified (Figures 4B, 4C). Because a
similar decrease in CD11c expression was not observed in CD82
cDC in vivo (data not shown), the significance of this observation
remained uncertain. To further examine Mac1+ (CD82 equiv-
alent) cDC development, we cultured bone marrow cells with the
cytokine GM-CSF, which has previously been shown to
exclusively generate CD82 cDC equivalents, but not CD8+
cDC equivalents or pDC [34,36]. Under these culture conditions,
we did not observe a defect in the production of Pin1-null Mac1+
cDC, nor did we detect differences in the expression of CD11c
(Figures 4B, 4C). Based on our collective results, we conclude that
Pin1 is unlikely to have a substantial role in the development of the
CD82 subset of cDC.
Consistent with results obtained from freshly isolated bone
marrow cells, the generation of pDC was unaltered in Pin1-null
bone marrow cultures, further indicating that Pin1 is dispensable
for pDC development (Figure 4D). To further investigate the
possibility that the absence of Pin1 imparts a general develop-
mental deficiency on bone marrow progenitors, Pin1-null bone
marrow was also assayed for its ability to produce macrophages,
cells that share common myeloid progenitors with DC and
similarly undergo the final stages of development in peripheral
tissues (Figure S3) [37]. After 6 days in culture with the cytokine
macrophage colony stimulating factor (M-CSF), both adherent
and non-adherent cells were collected and stained. No defect was
found in the generation of macrophages from Pin1-null bone
marrow cultures (Figure 4D). Taken together, the absence of
defects in the generation of both pDC and macrophages in Pin1-
null bone marrow cultures indicates that Pin1 may be preferen-
tially required for late stages of cDC development.
To determine whether the decrease in Mac1- (CD8+ equivalent)
cDC observed in Pin1-null cultures resulted from decreased
proliferation or survival, we compared total cell numbers and
propidium iodide (PI) uptake between WT and Pin1-null cells. We
did not detect any differences in the total number of cells recovered
on day 9 of culture, nor did we observe any dissimilarities in the
frequency of live (PI2) cells (Figure 5A). These results indicate that
the decrease in Pin1-null Mac1- cells is unlikely to be due to altered
proliferation or survival. Another possible explanation for decreased
Pin1-null Mac1- cDC is an impairment in the production of the
immediate precursor to Mac1- cDC. A population of pre-cDC that
preferentially gives rise to both the CD8+ cDC equivalent and
CD103+ DC, but not CD82 cDC, has recently been described in
FL bone marrow cultures [38]. Although the authors utilized
transgenic cells expressing GFP-Id2 to identify this population, the
cells were further characterized as CD11c+MHCII-B220+PDCA1-
Sirpa-CD24+. We collected WT and Pin1-null cells between days 3
and 9 of culture with FL and determined the frequency of
CD11c+MHCII-B220+PDCA1-Sirpa-CD24+ cells. We were un-
able to detect differences in this population between WT and Pin1-
nullculturesonanyofthe daysassessed (Figure4B).It ispossiblethat
without gating on Id2-expressing cells we were unable to accurately
identify this subset of pre-cDC. Additionally, we cannot exclude the
possibilitythatthereexistsadefectinanotherpopulationofPin1-null
pre-CD8+ cDC that has not yet been identified.
Similar to Mac1 expression, the expression of Sirpa and CD24
have been used to distinguish between CD8+ and CD82 subsets
of cDC both in vivo and in ex vivo FL cultures [38,39]. To confirm
our previous results, we used these additional markers to identify
Figure 2. Pin1-null mice have fewer steady-state spleen cDC and fewer FL-expanded CD8+ cDC in vivo. (A) Quantitation of the numbers
of steady-state spleen DC subsets from healthy WT and Pin1-null mice. Cell population numbers were determined by multiplying the frequency of
the cell population by the total number of splenocytes obtained from each mouse (n=6). Definitions of each cell population can be found in
Materials and Methods. (B) Quantitation of the numbers of spleen DC subsets from WT and Pin1-null mice that were administered 1 mg Flt3 Ligand
(FL) for 9 consecutive days. Cell population numbers were determined by multiplying the frequency of the cell population by the total number of
splenocytes obtained from each mouse (n=5).
doi:10.1371/journal.pone.0029808.g002
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alent) and B220-MHCII+CD24(lo)Sirpa+ (CD82 equivalent)
cDC populations. Consistent with results obtained by gating on
Mac1 expression, Pin1-null FL cultures exhibited a significant
decrease in the CD24+Sirpa2 (CD8+ equivalent) cDC population
of cells compared to WT cultures. Furthermore, the CD24(lo)-
Sirpa+ (CD82 equivalent) cDC population was not significantly
altered in the absence of Pin1 (Figure S5). The ability of ex vivo
bone marrow cultures to recapitulate the reduced number of
CD8+ cDC observed in Pin1-null spleens suggests that Pin1
functions as a modulator of late CD8+ cDC development.
Pin1 is dispensable for LPS-induced MHC class II and
co-stimulatory molecule expression
When cDC encounter foreign antigen they become activated
and undergo maturation, a process that endows them with the
Figure 3. DC bone marrow progenitors are unaltered in absence of Pin1. (A) Normalization of total bone marrow cells from WT and Pin1-
null mice by weight (grams). WT and Pin1-null mice were weighed upon euthanization. The normalized graph was generated by dividing the total
number of bone marrow cells by the body weight (grams) of each mouse (n=6). (B) Quantitation of normalized numbers of bone marrow
progenitors in both WT and Pin1-null mice. KLS, c-kit+Lin-sca1+ stem cells; CLP, common lymphoid progenitor; CMP, common myeloid progenitor;
GMP, granulocyte-macrophage progenitor; MDP, macrophage-dendritic cell progenitor; CDP, common dendritic cell progenitor. Total cell numbers
were determined by multiplying the frequency of each population by the total number of bone marrow cells. Total population numbers were then
normalized to body weight by dividing the number of cells in each population by the body weight (grams) of each mouse (n=6). (C) Quantitation of
normalized numbers of pre-cDC and pDC in the bone marrow of WT and Pin1-null mice. Normalized cell numbers were calculated as described in (B)
(n=6).
doi:10.1371/journal.pone.0029808.g003
Pin1 Modulates Development of CD8+ cDC
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29808Figure 4. DC development in bone marrow cultures. (A) Representative FACS plots of WT and Pin1-null bone marrow-derived Mac1- cDC
generated by culturing with FL. Cells were previously gated as B220-Mac12 (‘‘Mac12’’) and cDC are identified as MHCII
hiCD11c
hi cells. The frequency
of Mac12 cDC corresponding to the populations gated in the FACS plots on the left are graphed on the right as percentage of total cells (n=16).
(B) Representative FACS plots of WT and Pin1-null bone marrow-derived Mac1+ cDC generated by culturing with either FL (n=16) or GM-CSF (n=11).
FL-generated cells were previously gated as B220-Mac1+, and GM-CSF-generated cells were previously gated as B220-Mac1+GR1-. In the plots shown,
cDC are identified as MHCII
hiCD11c
hi cells. The frequencies of Mac1+ cDC gated on the left are depicted in the graph on the right as the percentage of
total cells. (C) Representative overlaid histograms comparing CD11c expression in WT and Pin1-null B220-Mac1+ cells generated from FL and GM-CSF
bone marrow cultures. (D) Representative FACS plots of WT and Pin1-null bone marrow-derived pDC and macrophage (mW). Cells were not
previously gated. pDC are identified as PDCA1+CD11c
int cells and macrophages are identified as F4/80+Mac1+ cells. The frequencies of WT and Pin1-
null bone marrow-derived pDC (n=16) and macrophages (n=6) are shown in the graph on the right as percentage of total cells.
doi:10.1371/journal.pone.0029808.g004
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alters cDC maturation, day 9 FL bone marrow cultures were
incubated with LPS for 24 hours and analyzed for the expression
of MHC class II and the co-stimulatory molecules CD40 and
CD86, which are induced upon maturation. Upon LPS stimula-
tion, the defect in CD11c expression present in unstimulated Pin1-
null Mac1+ cDC became undetectable; both WT and Pin1-null
cells expressed CD11c to the same extent (Figure 6A). While the
reason for decreased CD11c expression in FL cultures remains
unclear, it does not appear that this defect extends to mature
Mac1+ cDC, and is therefore unlikely to directly impact the ability
of DC to stimulate adaptive immune responses.
When analyzed for the expression of MHC class II, CD40
and CD86, both Mac1- and Mac1+ subsets of Pin1-null cDC
expressed each of these molecules to the same extent as WT cells
when stimulated with LPS (Figure 6A, 6B). Neither WT nor Pin1-
null pDC increased expression of these proteins, as was expected
since pDC lack TLR4 and are unable to respond to LPS
(Figure 6C). Thus, although there are fewer Pin1-null Mac1- cDC,
those cells that develop are capable of up-regulating MHC class II
and co-stimulatory molecule expression in response to LPS.
CD8+ T cell response in Pin1-null mice infected with
Listeria monocytogenes
The most robust defect observed in Pin1-null mice and Pin1-
null bone marrow cultures was impaired generation of CD8+
cDC. To test the hypothesis that decreased CD8+ cDC in Pin1-
null mice would impact the proliferation of CD8+ T cells in vivo,
mice were infected with Listeria monocytogenes (L.m.), an intracellular
bacterium that has been demonstrated to both activate CD8+
cDC and induce CD8+ T cell priming [40,41,42]. To eliminate
the possibility that a detectable difference in T cell expansion
might result from a T cell-intrinsic defect in the absence of Pin1,
WT and Pin1-null mice were injected with WT transgenic CD8+
T cells from OT1 mice. These cells express an ovalbumin(ova)-
specific T cell receptor as well as the CD45 allelic variant CD45.1,
which allowed them to be distinguished from endogenous
CD45.2-expressing cells. Twenty-four hours after receiving
10,000 OT1 CD8+ T cells, WT and Pin1-null mice were
administered 1610
4 CFU of live L.m. engineered to express
ovalbumin, thereby enabling the induction of a strong response
from the ova-specific OT1 CD8+ T cells. Seven days after L.m.
infection, mice were euthanized and splenocytes were stained for
CD45.1+ CD8+ T cells. Pin1-null mice accumulated 50% fewer
CD45.1+ CD8+ T cells than WT mice (Figure 7A).
To determine the specificity of defective CD8+ T cell
proliferation in Pin1-null mice, we also examined the proliferation
of adoptively transferred WT CD4+ T cells. Both WT and Pin1-
null mice were injected with 1–2 million CFSE-labeled WT CD4+
T cells from OT2 mice, which also express an ova-specific T cell
receptor. Twenty-four hours later, mice were injected with ova
peptide (323–339) to stimulate proliferation of ova-specific CD4+
T cells. After an additional 48 hours, splenocytes were collected
and stained to identify CFSE+ CD4+ T cells. A single peak
corresponding to CFSE bright CD4+ T cells was detected in both
WT and Pin1-null control mice that did not receive ova peptide.
As expected, the CD4+ T cells of mice that received ova exhibited
multiple peaks of decreasing CFSE intensity, which correspond to
successive rounds of cell division. No defects were observed in the
proliferation of adoptively transferred CD4+ OT2 cells in Pin1-
null mice. Rather, it appeared that CD4+ T cell proliferation was
mildly enhanced in the absence of Pin1, as there was a slight shift
towards more CFSE dilute CD4+ T cells in Pin1-null mice
(Figure 7B). Taken together, these results are consistent with
impaired CD8+ cDC development in Pin1-null mice and suggest
that such a defect has the ability to impair CD8+ T cell
proliferation in vivo.
Pin1 regulates expression of PU.1
To further understand how Pin1 modulates cDC development,
immunoblot analysis was performed on lysates from WT and
Pin1-null FL-generated bone marrow DC (FLDC). The expression
Figure 5. Cell survival and pre-cDC generation in bone marrow
cultures. (A) The graph on the left shows the quantitation of the total
number of WT and Pin1-null bone marrow-derived dendritic cells
recovered from bone marrow cultures after 9 days incubation with FL.
The graph on the right is a quantitation of the frequency of live WT and
Pin1-null bone marrow-derived DC that did not stain with propidium
iodide (PI2) (n=3). (B) The top panel depicts part of the gating strategy
used to identify pre-cDC. Previously gated PDCA1-CD11c+ cells were
further gated, as shown, to identify PDCA1-CD11c+MHCII-B220+ Sirpa-
CD24+ pre-cDC in FL cultured bone marrow cells. The frequencies of
pre-cDC from WT and Pin1-null cultures are quantified in the graph
below as percentage of total cells (n=3).
doi:10.1371/journal.pone.0029808.g005
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cDC development was measured, including IRF8, Id2, Gfi-1, and
PU.1 [33,43,44]. Although the expression of the other proteins
appeared to be unaltered (Figure S6), there was a marked increase
in PU.1 protein in Pin1-null FLDC. This same deregulation was
confirmed in Pin1-null mouse embryo fibroblasts (MEF), which
also express elevated levels of PU.1 protein (Figure 8A). To
determine whether increased PU.1 protein was the result of
elevated PU.1 mRNA, qRT-PCR analysis was performed on both
FLDC and MEF. No change in PU.1 mRNA was detected in
Pin1-null FLDC. qRT-PCR analysis in MEF, however, revealed a
modest 1.5-fold increase in PU.1 mRNA in the absence of Pin1
(Figure 8B). As PU.1 is known to bind and regulate its own
promoter, we speculate that increased PU.1 mRNA in Pin1-null
MEF might result from enhancement of this feed-forward loop.
The absence of the same increase in PU.1 mRNA in FLDC,
however, may be indicative of additional defects in PU.1
transcriptional activity. Indeed, PU.1 is known to interact with
multiple proteins that co-regulate transcription of target genes
[45]. Because several of these PU.1-binding proteins are absent in
MEF (Figure S6), it is possible that PU.1 transcriptional activity is
not regulated in the same manner in MEF as in FLDC.
It was recently published that GST-Pin1 binds endogenous
PU.1 in PMA-stimulated THP-1 human macrophages [15]. This
interaction was confirmed by performing a GST pull-down assay
in both WT and Pin1-null MEF and showing that endogenous
PU.1 is able to bind WT GST-Pin1. The inability of a WW
binding domain mutant of GST-Pin1 (W11A, W34A) to bind
PU.1 indicated that this domain of Pin1 is necessary to maintain
the interaction with PU.1 (Figure 8C), as was previously reported
in COS-7 cells [15]. Three putative Pin1 binding sites exist in the
PU.1 protein, two of which are located in the PEST domain.
Because PEST domains have been shown to modulate the
degradation of other proteins, the ability of Pin1 to regulate
PU.1 protein turnover was examined [46]. Both WT and Pin1-
null MEF were incubated with the protein synthesis inhibitor
Figure 6. Pin1-null bone marrow-derived DC up-regulate costimulatory molecule expression in response to LPS. (A) Representative
histograms showing expression of MHC class II (MHCII) and costimulatory molecules in WT and Pin1-null Mac1+ bone marrow-derived DC that were
unstimulated or stimulated with 100 ng/ml LPS for 24 hours. The upper panel shows a histogram of CD11c expression in previously gated B220-
Mac1+ cells. The gate shown in the histogram was applied to further analyze all CD11c+ cells for the expression of MHC class II (MHCII), CD40, and
CD86 in the lower panels. Histograms represent data acquired from two independent experiments (n=6). (B) Representative histograms showing
expression costimulatory molecules in WT and Pin1-null Mac12 bone marrow-derived DC that were unstimulated or stimulated with 100 ng/ml LPS
for 24 hours. The upper panel shows FACS plots of Mac12 cDC that were previously gated as B220-Mac12. The gate in the upper panel
(MHCII+CD11c+ gate) was applied to further analyze Mac12 cDC for the expression of CD40 and CD86 in the lower panels. Histograms represent data
acquired from two independent experiments (n=6). (C) Representative histograms showing expression of MHC class II (MHCII) and costimulatory
molecules in WT and Pin1-null bone marrow-derived pDC that were unstimulated or stimulated with 100 ng/ml LPS for 24 hours. pDC were
previously gated as PDCA1+CD11c+. Histograms represent data acquired from two independent experiments (n=6).
doi:10.1371/journal.pone.0029808.g006
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immunoblot analysis. The absence of Pin1 was found to promote
PU.1 stability, nearly doubling its half-life (Figure 8D). These data
further expand on the recently-described interaction between Pin1
and PU.1 by providing new evidence that Pin1 facilitates PU.1
protein degradation.
Discussion
This work was begun to identify a role for Pin1 in modulating
systemic inflammation, as such a role had not yet been described.
Three hours after administration of LPS, Pin1-null mice did not
exhibit defects in circulating levels of two classic pro-inflamma-
tory cytokines, IL-6 and TNFa. This result initially seems to
contradict the recent claim that Pin1 regulates serum IL-6
production in a model of endotoxic shock [15]. In that report,
however, measurements were taken 24 hours after challenge, a
time point at which circulating levels of cytokines have previously
been shown to be in decline [47,48]. For this reason, we do not
believe that our results are directly comparable to those data
previously described. Upon staining splenocytes, an impairment
in the accumulation of spleen cDC was identified in Pin1-null
mice. Although 18 hours after challenge is not a typical time to
measure cDC accumulation, we nonetheless observed a defect
that suggested to us that Pin1 may play some role in cDC biology,
which has not been described. Indeed, further investigation into
this unexpected result uncovered a novel role for Pin1 in
regulating steady-state production of CD8+ cDC. We observed
significant decreases in both the total number and frequency of
steady-state CD8+ spleen cDC in Pin1-null mice. Additionally,
Pin1-null mice were significantly impaired in their ability to
accumulate CD8+ cDC, but not CD82 cDC or pDC, in
response to in vivo administration of FL.
In order to determine whether the observed defect in spleen
CD8+ cDC accumulation resulted from defects in Pin1-null bone
marrow cells, DC progenitors and pre-cDC were quantified in the
bone marrow of WT and Pin1-null mice. No defects in progenitors
or pre-cDC were observed in the bone marrow of Pin1-null mice,
indicating that Pin1 is not required for early stages of cDC
development. Similar results have been obtained in both Batf3-
Figure 7. Impaired CD8+ T cell proliferation in Pin1-null mice infected with Listeria monocytogenes. (A) Representative FACS plots of
donor WT CD45.1+CD8+ OT1 T cells isolated from spleens of CD45.2+ WT and Pin1-null mice that were previously injected with 10,000 WT
CD8+CD45.1+ ova-specific T cells and then either left uninfected or infected with L.m.-ova for 7 days. Cells were previously gated as CD3+. The graph
on the right is a quantitation of WT CD45.1+CD8+ OT1 T cells obtained from the spleens of WT and Pin1-null mice. Total numbers of CD8+ CD45.1+
cells were determined by multiplying the cell frequency by the total number of splenocytes obtained from each mouse (n=4). (B) The plots on the
left show the previous gates used to identify donor WT CFSE+ CD4+ OT2 T cells isolated from spleens of WT and Pin1-null mice that were previously
injected with 1–2 million WT CSFE-labeled ova-specific CD4+ T cells. The four panels in the center are representative histograms (n=3) showing CFSE
intensity in WT and Pin1-null mice that were either unchallenged (ctrl) or injected with ova peptide (ova). The overlaid histogram on the right is an
additional depiction of the two ova histograms to directly compare CFSE intensity between CD4+ T cells derived from WT and Pin1-null mice.
doi:10.1371/journal.pone.0029808.g007
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marrow pre-cDC despite exhibiting impaired CD8+ cDC
development [49,50]. Because pDC fully develop within the bone
marrow, they were also quantified. The absence of Pin1 did not
alter numbers of bone marrow pDC, indicating that Pin1 is not
required for the development of this subset.
Figure 8. Pin1 modulates PU.1 protein stability. (A) Immunoblot analysis of PU.1 protein expression in WT and Pin1-null FL-cultured bone
marrow-derived DC (FLDC) and primary MEF. For FLDC, the immunoblot shown is representative of cells derived from 3 different mice. For MEF, the
immunoblot shown is representative of 3 different experiments. (B) Quantitation of PU.1 mRNA expression from WT and Pin1-null FLDC (n=5) and
MEF (n=3). (C) GST-Pin1 pull down in WT and Pin1-null MEF lysates. 1 mg of total lysate was incubated with GST alone, WT GST-Pin1, or WW GST-Pin1
for 2 hours. After binding, beads were washed, resuspended in SDS-Page sample buffer, boiled, and then analyzed by immunoblot. Membranes were
probed for expression of PU.1. (D) PU.1 protein expression in WT and Pin1-null MEFs after being treated with 150 mg/ml cycloheximide (CHX) to
inhibit protein synthesis for 2, 4, 6, 8, or 10 hours. The immunoblot shown is representative of two independent experiments. PU.1 protein expression
is plotted in the bottom graph as a percentage of total PU.1 protein at time zero, and reflects the values obtained from immunoblots shown directly
above.
doi:10.1371/journal.pone.0029808.g008
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unperturbed in the bone marrow of Pin1-null mice, we utilized
established ex vivo bone marrow culture protocols to examine later
stages of cDC development. Because cDC in FL cultures do not
express CD8, other cell surface markers have previously been
used to distinguish between the CD8+ and CD82 cDC
equivalents. We stained FLDC for two different sets of markers
that have been described to specifically discriminate between the
two cDC subsets. Both sets of markers clearly indicated a
significant defect in the CD8+ cDC equivalent subset of cDC in
Pin1-null cultures, which mirrored the defect identified in steady-
state CD8+ cDC in vivo. Upon quantifying the CD82 cDC
equivalent population in bone marrow cultures, we encountered
slightly more complex results. When cultured with FL and gated
on Mac1 expression, Pin1-null Mac1+ (CD82 equivalent) cDC
expressed less CD11c than WT Mac1+ cDC. To help clarify this
result, bone marrow was also cultured with GM-CSF to
exclusively produce the Mac1+ (CD82 equivalent) subset of
cDC. Under these conditions, Pin1-null Mac1+ cDC production
was not impaired, nor was there any observable decrease in
CD11c expression. Additionally, when FL cultured cells were
alternately stained with CD24 and Sirpa, which have previously
been used to discriminate between cDC subsets, we did not
observe a decrease in the Pin1-null CD82 cDC equivalent cells,
which are defined as CD24(lo)Sirpa+ cells. Taken together, these
results indicate that Pin1 is unlikely to be required for the
development of CD82 cDC. Conversely, Pin1 appears to
modulate the development of CD8+ cDC, as indicated by the
significant decrease in CD8+ equivalent cDC that was consis-
tently observed in Pin1-null bone marrow cultures.
Coupling our observations in Pin1-null mice to the results from
our ex vivo bone marrow culture system indicates a role for Pin1in
preferentially regulating the development of the CD8+ subset of
cDC. Few proteins have been described to regulate the
development of one particular DC subset, as many are
transcription factors that regulate early stages of development
[51]. Although more restricted transcription factors have been
identified, including IRF8 and Id2 [43], many of these proteins
have been reported to possess additional roles in regulating the
development and/or function of other hematopoietic lineages
[44,52,53,54,55]. While we cannot rule out subtle defects in the
development of other subsets of DC, Pin1 appears to be
particularly important for the production of CD8+ cDC. We
find this interesting since, compared to the CD82 subset of cDC,
CD8+ cDC have been shown to exhibit more rapid BrdU
labeling kinetics, indicating that these cells are produced and
turned over more quickly than CD82 cDC [56,57]. Additionally,
under conditions that stimulate DC expansion in vivo, such as
challenge with monophosphoryl lipid A, injection of FL, and
bone marrow transplantation, the CD8+ subset of cDC has been
demonstrated to exhibit the greatest degree of expansion [56,58].
Accordingly, it is conceivable that delayed development in the
absence of Pin1 could give rise to a more pronounced defect in
the accumulation of the CD8+ subset of cDC, which is rapidly
turned over in vivo. Such a scenario would be consistent with
previously described roles for Pin1 as a rate-limiting modulator of
precisely timed processes.
To address whether the observed defect in the production of
Pin1-null CD8+ cDC can influence adaptive immune responses
in vivo, we evaluated the effects of a pathogen that induces CD8+
cDC activation as well as CD8+ T cell priming. Acknowledging
that Pin1 has already been shown to regulate the production of
type I interferons in response to either poly (I:C) or virus
[14,16], we infected mice with Listeria monocytogenes (L.m.),a n
intracellular bacterium that has been demonstrated to induce
CD8+ T cell proliferation. L.m.-infected Pin1-null mice were
found to be defective in their ability to expand adoptively
transferred WT CD8+ Tc e l l s .B e c a u s eC D 8 + cDC have
previously been shown to stimulate proliferation of CD8+ T
cells [40,41], these results are consistent with reduced produc-
tion of CD8+ cDC observed in Pin1-null mice. Furthermore,
these data support the idea that manipulation of Pin1 may be
valuable for modulating CD8+ cDC-dependent immune re-
sponses in vivo.
To investigate how Pin1 modulates cDC development, the
expression of several proteins reported to participate in DC
development was determined. Immunoblot analysis revealed that
Pin1-null FLDC and MEF expressed greater amounts of PU.1
protein than WT cells. When PU.1 mRNA levels were measured,
there appeared to be a discrepancy between FLDC and MEF;
PU.1 mRNA was unchanged in Pin1-null FLDC, but slightly
elevated in MEF. This modest increase in PU.1 mRNA in MEF
may be due to the ability of PU.1 to bind its own promoter and
activate transcription [45]. As transcriptional activity appears to be
cell-type dependent and regulated by coordinated interactions
with other cell-specific proteins, it is possible that differences exist
between FLDC and MEF in the regulation of PU.1 activity [59].
This hypothesis is supported by the fact that previously-described
PU.1 binding proteins, such as IRF8 and Gfi-1, were undetectable
in MEF [60,61].
The abundance of PU.1 protein varies between different
lineages and developmental stages, indicating that regulated
changes in expression may be important, and perhaps instructive,
for lineage-specific development of both myeloid and lymphoid
cells [62,63]. The role of PU.1 in DC development is not fully
understood, and appears to be quite complex. Indeed, PU.1 can
both positively and negatively regulate gene transcription, and its
activity is influenced by interaction with other proteins as well as
phosphorylation [45,60,61,64,65]. Two putative Pin1 binding
sites are located within the PEST domain of PU.1, a region that
has been shown to mediate interactions between PU.1 and other
proteins [61]. Our results confirm the recent report that Pin1
binds to PU.1, and that this interaction is abolished upon
mutation of the Pin1 WW domain [15]. Adding to the
understanding of this relationship, Pin1 was determined to
regulate PU.1 protein turnover, as indicated by the doubling of
PU.1 protein half-life in the absence of Pin1. Modulating protein
degradation is a common mechanism by which Pin1 regulates the
activity of its substrates. Indeed, Pin1 has also been shown to
regulate the stability and turnover of other hematopoietic
transcription factors, including NF-kB p65, IRF3, and Bcl6
[8,14,66]. Although we do not provide direct evidence, it is
tempting to speculate that Pin1 might regulate CD8+ cDC
development through cell-specific modulation of PU.1 activity,
which could be achieved by regulating PU.1 degradation rate,
interactions with binding partners, and perhaps dephosphoryla-
tion, as has been shown for other Pin1 substrates [2,67,68].
Further work is required to understand how Pin1 binding to PU.1
is regulated, and how this interaction might impact PU.1
function.
In conclusion, we have expanded the current understanding of
DC development by identifying a novel role for Pin1 in regulating
the steady-state production of CD8+ cDC. The absence of Pin1
impairs FL-induced expansion of CD8+ cDC and also prevents
robust proliferation of WT CD8+ T cells following bacterial
infection in mice. Collectively, these results establish Pin1 as an
important modulator of CD8+ cDC development, and further
implicate Pin1 as a regulator of innate immunity.
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All animal work was conducted under Duke University
Institutional Animal Care and Use Committee protocol numbers
A073-09-03 (ARM) and A172-09-06 (YWH).
Mice
CD45.2+ Pin1 2/2 mice were generated as previously
described and maintained in a pure C57BL/6 background along
with WT littermates [3].
Reagents
Lipopolysaccharide from Escherichia coli, Sigma L2637; Hanks
Balanced Salt Solution (HBSS) without calcium, magnesium and
phenol red, Mediatech, Inc. 21-022-CV; EDTA-coated Micro-
tainers, BD Biosciences 365974; Serum separator tubes, BD
Biosciences 365956; IL-6 ELISA Max kit, BioLegend 431302;
TNFa ELISA Max kit, BioLegend 430902; Dulbecco’s Modified
Eagle’s Medium (DMEM), Mediatech, Inc. 17-205-CV; heat-
inactivated Fetal Bovine Serum (hiFBS), Gemini BioProducts 900-
108; recombinant mouse Flt3 Ligand, R&D 427-FL/CF;
recombinant mouse GM-CSF, eBioscience BMS325; recombinant
mouse M-CSF, eBioscience 14-8983; 16 RBC Lysis Buffer,
eBioscience 00-4333-57; CFDA-SE Cell Tracer Kit, Invitrogen
V12883; ovalbumin (ova) peptide (323–339), AnaSpec 27025;
Sigma Adjuvant System, Sigma-Aldrich S6322; Cycloheximide,
Calbiochem 239763.
Measurement of circulating cytokines by ELISA
Three hours after injection of LPS, blood was either obtained by
tail vein bleed, or from cardiac puncture after euthanization. Tail
vein blood was collected in EDTA-coated microtainers and then
centrifuged at 5,000 rpm and 4uC for 15 minutes to pellet cells.
Supernatant was collected (plasma) and cytokines were measured
by ELISA. Blood from cardiac puncture was collected in a serum
separator tube and centrifuged at 10,000 rpm for 10 minutes at
room temperature to separate serum. Serum was removed from
top fraction and cytokines were measured by ELISA.
Isolation of splenocytes and bone marrow cells
To obtain splenocytes, spleens were removed and crushed on
ice in DMEM-BM (DMEM supplemented with Pen/Strep, 10%
hiFBS, 2 mM L-glutamine, 1 mM Sodium Pyruvate, MEM Non-
essential Amino Acids, 10 mM HEPES, and 0.1% b-Mercapto-
ethanol). To obtain bone marrow cells, both femurs and tibias
were removed and the marrow was flushed out of the bones with
DMEM-BM using a needle and syringe. For both splenocytes and
bone marrow cells, erythrocytes were removed by lysis in 16RBC
Lysis Buffer for 4–6 minutes on ice. Cells were then washed,
passed through a 70 mm cell strainer, counted, and either directly
stained or put into culture.
Staining and flow cytometry
Between one and five million cells were washed in FACS Buffer
(HBSS containing 3% hiFBS, 0.1% NaN3, and 10 mM EDTA)
and then pelleted, resuspended in 100 ul Antibody Dilution Buffer
(FACS Buffer supplemented with 5% Normal Mouse Serum, 5%
Normal Rat Serum, and 1% purified anti-CD16/32(FccR)), and
incubated on ice for 15 minutes. Primary antibodies were then
added to cells in Antibody Dilution Buffer (ADB) for 25 minutes
on ice. Cells were washed in 1 ml FACS Buffer, resuspended in
FACS Buffer, and then analyzed immediately using a BD
FACSCanto II analyzer. For the staining of GMPs in the bone
marrow, 1% purified anti-CD16/32(FccR) was excluded from the
ADB and replaced with CD16/32(FccR)-PE-Cy7. After 15 min
on ice, the remaining primary antibodies were added to the cells
for 25 min on ice, and the rest of the staining protocol was carried
out as described above. F4/80-FITC, CD11c-APC, MHC class II
(I-A)-FITC, B220-PE, B220-PE-Cy7, CD69-APC, CD4-PE,
CD45.1-FITC, CD3-FITC, CD3-PE, CD8-PerCP-Cy5.5, CD8-
PE, GR1-PE, CD115-APC, PDCA1-biotin, PDCA1-APC, CD19-
FITC, CD40-PE, c-Kit-FITC, c-Kit-APC, Flt3-PE-Cy5, IL7Ra-
PE-Cy7, CD34-FITC, Sca-1-PE-Cy5.5, CD16/32(FccR)-PE-Cy7,
Mac1-PE, Ter119-PE, Sirpa(CD172a)-APC, purified anti-CD16/
32, Normal Rat Serum, and Normal Mouse Serum were all
purchased from eBioscience. CD86-APC, CD40-PE-Cy7, CD86-
PE-Cy7, GR1-APC-Cy7, CD3-PE-Cy7, CD11c-PerCP-Cy5.5,
CD11c-PE-Cy7, Mac1-Pacific Blue, CD19-PE-Cy7, CD24-PE,
and Sca-1-Pacific Blue were all purchased from BioLegend.
CD19-PE and CD3-APC were purchased from Pharmingen.
Streptavidin-APC-Cy7 was purchased from BD Biosciences.
Definitions of identified cell populations
Flow analysis was performed using FlowJo software (TreeStar,
Inc). For mice injected with LPS or vehicle: mature spleen cDC
were identified as MHCII
hiCD11c
hi cells, spleen B cells were
identified as B220+CD32 cells, and spleen T cells were identified
as B220-CD3+ cells. Activated B cells and T cells were further
defined as CD69+ cells. For steady-state spleen DC and FL-
expanded spleen DC: CD8+ cDC were identified as CD3-CD19-
PDCA1-GR1-CD11c
hiMac1-CD8+ cells, CD82 cDC were
identified as CD3-CD19-PDCA1-GR1-CD11c
hiMac1+CD82
cells, pDC were identified as Mac1-PDCA1+CD11c
int cells, and
total cDC were calculated as the sum of CD8+ cDC and CD82
cDC. For bone marrow progenitors: Lineage (Lin) stain contained
CD3, CD4, CD8, CD19, Mac1, GR1, B220, and Ter119. KLS
were identified as c-kit+Lin-Sca-1+ cells, CLP were identified as
Lin-c-kit
losca-1
loIL-7R+ cells, CMP were identified as Lin-c-
kit+sca-1
loCD34+FccR
lo cells, GMP were identified as Lin-c-
kit+sca-1
loCD34+FccR
hi cells, MDP were identified as Lin-
CD115+IL7R-c-kit+Flt3+ cells, and CDP were identified as Lin-
CD115+IL7R-c-kit
loFlt3+ cells. Additional bone marrow popula-
tions: pre-cDC were identified as PDCA1-MHCII-GR1-CD11c+
cells, and pDC were identified as PDCA1+CD11c+ cells. For bone
marrow-derived DC cultures: CD8+ cDC equivalent cells were
identified as B220-Mac1-MHCII
hiCD11c
hi cells (‘‘Mac12’’) or
PDCA1-CD11c+B220-MHCII+CD24+Sirpa2 cells; CD82 cDC
equivalent cells were identified as B220-Mac1+ MHCII
hiCD11c
hi
cells (‘‘Mac1+’’) or PDCA1-CD11c+B220-MHCII+CD24
loSirpa+
cells; pre-cDC were identified as PDCA1-CD11c+ MHCII-
B220+CD24+ Sirpa2 cells; pDC were identified as PDCA1+
CD11c
int cells. For bone marrow-derived macrophages: Macro-
phages were identified as F4/80+Mac1+ cells. For mice injected
with OT1 CD8+ T cells followed by L.m. or control: donor OT1
CD8+ T cells were identified as CD3+CD45.1+CD8+ cells. For
mice injected with OT2 CD4+ T cells followed by ova or control:
donor OT2 CD4+ T cells were identified as CD3+CD8-CD4+
CFSE+ cells.
In vivo administration lipopolysaccharide
WT and Pin12/2mice were administered either 300 ml HBSS
or 15 mg/kg lipopolysaccharide diluted in 300 ml of HBSS by i.p.
injection. Mice were euthanized after 3 or 18 hours.
In vivo administration of Flt3 Ligand
WT and Pin12/2mice were administered 1 mg of Flt3 Ligand
in 300 ml HBSS by i.p. injection for 9 consecutive days. Mice were
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by flow cytometry.
Infection with Listeria monocytogenes and analysis of
CD8+ T cells
Ovalbumin(ova)-specific OT1 CD8+ T cells were obtained
from the spleen of an OT1 CD45.1/2 female in a C57BL/6
background using the EasySep CD8+ T cell Enrichment Kit
(StemCell Technologies, 19753) according to the manufacturer’s
protocol. 100 ml of PBS containing 10,000 ova-specific CD45.1/
2+ OT1 CD8+ T cells was then injected into the tail vein of each
CD45.2+ WT and Pin12/2mouse. Recombinant Listeria monocy-
togenes (L.m.) engineered to secrete chicken ovalbumin was kindly
provided by M. Bevan (University of Washington, Seattle, WA)
and was prepared as previously described [69]. Twenty-four hours
after the injection of OT1 CD8+ T cells, mice were either left
uninfected (controls) or infected with 10,000 CFU L.m.-ova in
100 ml PBS by tail vein injection. Seven days after L.m.-ova
infection, mice were euthanized and their spleens removed and
analyzed for the presence of CD45.1+ CD8+ T cells by flow
cytometry.
Ova challenge and analysis of CD4+ T cells
Ovalbumin(ova)-specific OT2 CD4+ T cells were obtained
from the spleens of OT2 CD45.2 mice in a C57BL/6 background
using the CD4+ T cell Isolation Kit II (Miltenyi, 130-095-248).
Purified cells were then labeled with CSFE for 5 min at room
temperature. 1–2 million cells were injected into WT and Pin1-
null mice by tail vein injection. Twenty-four hours after injection
of labeled CD4+ T cells, half of the mice received an
intraperitoneal injection of 20 ug ova(323–339) resuspended in
200 ul of Sigma Adjuvant System. Forty-eight hours after ova
injection, mice were euthanized and their spleens removed and
analyzed for the presence of CFSE+CD4+ T cells by flow
cytometry.
Generation of bone marrow-derived dendritic cells and
macrophages
FL bone marrow-derived DC (both cDC and pDC) were
generated by culturing bone marrow cells at 2610
6 cells/ml in
DMEM-BM (DMEM containing Pen/Strep, 10% hiFBS, 2 mM
L-glutamine, 1 mM Sodium Pyruvate, MEM Non-essential
Amino Acids, 10 mM HEPES, and 0.1% b-Mercaptoethanol)
supplemented with 50 ng/ml Flt3 Ligand for 9 days. On days 3
and 6, 40% of the media was removed and replaced with an
equal volume of DMDM-BM containing 50 ng/ml Flt3 Ligand.
On day 9, non-adherent cells were collected for analysis. GM-
CSF bone marrow-derived DC were generated by culturing
bone marrow cells at 2610
6 cells/ml in DMEM-BM supple-
mented with 5 ng/ml GM-CSF for 5 days. On day 5, non-
adherent cells were collected for analysis. Bone marrow-derived
macrophages were generated by culturing bone marrow cells at
2610
6 cells/ml in DMEM-BM supplemented with 15 ng/ml M-
CSF for 6 days. Both adherent and non-adherent cells were
collected for analysis. All cultured cells were maintained at 37uC
and 5% CO2.
In vitro stimulation of bone marrow-derived DC
Bone marrow-derived DC were generated by culturing with
Flt3 Ligand for 9 days. On day 9, 100 ng/ml LPS was added to
the media for 24 hours. Both adherent and non-adherent cells
were collected and analyzed by flow cytometry.
Immunoblot analysis
Cells were washed in HBSS and then lysed in TritonX Lysis
Buffer (150 mM NaCl, 10 mM Tris pH7.4, 10 mM EDTA,
50 mM NaF, and 1% TritonX-100) containing 100 mg/ml
Pefabloc (Roche, 11429876001), 10 mg/ml Leupeptin, and
100 nM Okadaic Acid. Lysates were then sonicated and clarified
by centrifugation at 10,000 rpm for 5 minutes. Lysates were
resolved on 10% or 12% SDS-Page gels and transferred to
nitrocellulose. Membranes were incubated in blocking buffer
(0.66PBS containing 0.25% Fish Gelatin, 0.5 mg/ml casein, and
0.02% sodium azide) for $1 hour at room temperature, or at 4uC
overnight, and then incubated with primary antibodies in blocking
buffer containing 0.1% Tween-20 at room temperature for
$2 hours. Membranes were washed in TBS containing 0.05%
Tween-20, and then incubated with secondary antibodies in
blocking buffer containing 0.1% Tween-20 and 0.01% SDS for
1 hour at room temperature. After washing, membranes were
scanned using the Odyssey Infrared Imager by Li-Cor Biosciences
and band intensities were quantified using Odyssey software v3.0.
The following commercially available antibodies were used: PU.1
(Cell Signaling, 2266S), IRF8 (Cell Signaling, 5628S), Id2 (Cell
Signaling, 3431S), Gfi-1 (Santa Cruz, sc-8558), and b-actin
(Sigma, A5441). The Pin1 antibody was generated as previously
described [70].
Cycloheximide analysis
Primary WT or Pin12/2MEF were grown to 85% confluency
in DMEM-MEF (DMEM containing 2 mM L-glutamine, 10%
hiFBS, and Pen/Strep). Media was then removed and replaced
with either DMEM-MEF alone or DMEM-MEF containing
150 mg/ml cycloheximide reconstituted in water. Cells were
incubated for 2–10 hours in the presence of cycloheximide. Both
adherent and non-adherent cells were collected, lysed, and
analyzed by immunoblot.
GST pull down assay
The pGEX-2TK vector alone or pGEX-2TK vector containing
either WT Xenopus Pin1 or a WW domain mutant of Xenopus Pin1
(W11A, W34A) were expressed in BL21(DE3) E. coli (Stratagene,
200131). Bacteria were lysed in PBS containing 1 mM DTT,
10 mM EDTA, and 100 mg/ml Pefabloc (Roche, 11429876001)
and then sonicated. TritonX-100 was added to produce a final
concentration of 1% TritonX-100 and lysates were clarified by
centrifugation at 12,000 rpm for 20 min at 4uC. GST and GST-
Pin1 fusion proteins were then purified by incubating 5 ml of
clarified bacterial lysates with 200 ml of a 50/50 slurry of
glutathione-agarose beads for 2 hours at 4uC. Beads were washed
in Passive Lysis Buffer (PBS containing 1 mM DTT, 10 mM
EDTA, and 1% TritonX-100) supplemented with Pefabloc and
stored at 4uC. Primary WT and Pin12/2MEF were grown to
85% confluency in DMEM-MEF (DMEM containing 2 mM L-
glutamine, 10% hiFBS, and Pen/Strep) and then lysed in Passive
Lysis Buffer (PLB) supplemented with 100 mg/ml Pefabloc, 10 mg/
ml Leupeptin, and 100 nM Okadaic Acid. Cell lysates were
sonicated and clarified by centrifugation. 1.2 mg of 1 mg/ml
lysates were pre-cleared with 20 mg GST beads for 15 minutes at
4uC. 1 mg of pre-cleared lysate was then incubated with 10 mg
GST beads, 10 mg GST-Pin1 beads, or 10 mg GST-Pin1WW
beads for 2 hours at 4uC. Beads were washed 4 times in 1 ml of
PLB, then pelleted, resuspended in SDS-Page Sample Buffer and
boiled to elute proteins. Samples were analyzed by immunoblot
analysis.
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RNA was purified from cells using the RNeasy Mini Kit
(Qiagen, 74104) following the manufacturer’s protocol. Genomic
DNA was removed by on-column digestion with DNaseI using the
RNase-free DNase Set (Qiagen, 79254). cDNA was generated
from 1–3 mg of total RNA using SuperScript II Reverse
Transcriptase (Invitrogen, 18064022). RNA was then removed
by digestion with RNaseH (Invitrogen, 18021–071). qRT-PCR
analysis was performed using SYBR Green (Invitrogen, 4312704)
and the Bio-Rad CFX96 real-time PCR detection system. The
following primers were used: PU.1 Forward: 59-GAGAAAGC-
CATAGCGATCACTACT GG -39 and PU.1 Reverse: 59- AT-
GTGGCGATAGAGCTGCTGTAG -39; Cyclophilin A Forward:
59- GAGCTGTTTGCAGACAAAGT TC -39 and Cyclophilin A
Reverse: 59-CCCTGGCACATGAATC CTGG -39.
Statistical analysis
Data were determined to be statistically significant (*) if p ,0.05
by student’s t-test. Error bars represent the standard error of the
mean.
Supporting Information
Figure S1 Spleen B cells and T cells are unaltered in
absence of Pin1. (A) Quantitation of B cells and T cells from
WT and Pin1-null mice that were administered vehicle or 15 mg/
kg LPS for 18 hours. Cell population numbers were determined
by multiplying the frequency of the cell population by the total
number of splenocytes obtained from each mouse (n=3).
(B) Quantitation of CD69+ (activated) B cells and T cells from
WT and Pin1-null mice that were administered vehicle or 15 mg/
kg LPS for 18 hours. Cell population numbers were determined
by multiplying the frequency of the cell population by the total
number of splenocytes obtained from each mouse (n=3).
(C) Quantitation of cDC from WT and Pin1-null mice that were
administered vehicle or 15 mg/kg LPS for 18 hours. Cell
population numbers were determined by multiplying the frequen-
cy of the cell population by the total number of splenocytes
obtained from each mouse (n=6).
(EPS)
Figure S2 Frequency of spleen DC subsets in WT and
Pin1-null mice. (A) Frequency of steady-state spleen DC subsets
from healthy WT and Pin1-null mice graphed as percentage of
total splenocytes (n=6). (B) Representative FACS plots of WT and
Pin1-null steady-state spleen DC subsets. cDC subset plots were
previously gated as CD3-19-PDCA1-GR1-CD11c
hi cells. pDC
plots were previously gated on Mac1- cells. These gates were used
to generate data graphed in (A). (C) Splenocytes from WT and
Pin1-null mice were counted. Total cell numbers are graphed and
the p value is indicated below (n=8).
(EPS)
Figure S3 Steady-state dendritic cell development.
(EPS)
Figure S4 Frequency of bone marrow populations.
(A) Frequency of bone marrow progenitors in both WT and
Pin1-null mice graphed as percentage of total bone marrow cells.
KLS, c-kit+Lin-sca1+ stem cells; CLP, common lymphoid
progenitor; CMP, common myeloid progenitor; GMP, granulo-
cyte-macrophage progenitor; MDP, macrophage-dendritic cell
progenitor; CDP, common dendritic cell progenitor (n=6). (B)
Frequency of pre-cDC and pDC from WT and Pin1-null bone
marrow graphed as percentage of total bone marrow cells (n=6).
(EPS)
Figure S5 Additional markers identifying cDC equiva-
lents in bone marrow cultures. Representative FACS plots
from WT and Pin1-null bone marrow cells cultured with FL for 9
days. Cells were previously gated as CD11c+PDCA1-B220- and
cDC subsets are identified as either CD24+Sirpa2 (CD8+
equivalent) cDC or CD24(lo)Sirpa+ (CD82 equivalent) cDC.
Frequencies are quantified in the graph at the bottom and shown
as percentage of total cells (n=3).
(EPS)
Figure S6 Immunoblot analysis of transcription factors
involved in DC development. Transcription factor expression
in WT and Pin1-null bone marrow-derived DC and MEF.
(EPS)
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